USP <1030> - Biological Assay Validation

What it says

Biological assays used to measure the potency or activity of biotechnological and biological products must be validated to demonstrate suitable accuracy, precision and specificity, accounting for the greater inherent variability of biological response-based methods compared with conventional physicochemical analytical methods.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Biological assays, such as cell-based potency assays, are inherently more variable than chemical assays because they depend on a living biological system's response, which this chapter's validation approach is specifically designed to account for rather than ignore.
• Because potency is often the quality attribute most directly tied to a biologic's clinical effect, a poorly validated or poorly controlled biological assay creates risk that extends well beyond typical analytical method concerns.
• Statistical approaches for evaluating biological assay data, including parallel-line and parallel-curve analysis, are a defining feature of this chapter and differ meaningfully from the simpler statistical treatments used for most chemical test methods.

What inspectors look for

• Whether biological assay validation accounts for the assay's inherent biological variability using appropriate statistical approaches, rather than applying chemical assay validation criteria unchanged.
• Whether assay system suitability and reference standard performance are checked and documented for each assay run, given the sensitivity of biological systems to run-to-run variation.
• Whether potency results trending outside historical variability are investigated for both assay performance issues and genuine product quality concerns.

Related regulations